Prospective Follow-up After MVA-BN Booster Vaccination

Prospective On-site Study for the Immunological Follow-up of Individuals Who Received Booster Vaccination With MVA-BN Against Mpox

POQS-Boosted is a prospective observational study during which individuals who received Booster vaccination against mpox with the MVA-BN vaccine will be invited to provide biological samples at multiple times over the course of two years.

Mpox caused a worldwide outbreak in 2022 and continues to circulate worldwide and causes sporadic cases in Belgium and elsewhere. In the last 10 days, the first cases infected with the probably more virulent clade Ib MPXV have been reported from men who have sex with men in Belgium, the Netherlands, and elsewhere, indicating circulating this viral clade in sexual networks. In Belgium, vaccination against mpox was ceased at the end of 2022 and evidence showed that antibody levels against MPXV have decreased since then, raising questions about sustained protectiveness and the potential for a new mpox outbreak to emerge.

POQS-Boosted is a prospective observational study during which individuals who received Booster vaccination against mpox with the MVA-BN vaccine will be invited to provide biological samples at multiple times over the course of two years.

Inclusion Criteria:

1. Is scheduled to receive a booster dose of MVA-BN
2. ≥18 years
3. Willingness to provide written informed consent
4. Willingness to follow the study schedule

Exclusion Criteria:

1. Past or current MPXV infection